Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 5:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Tourettes Disorder Clear all
Not listed Not applicable Interventional

A Clinical Study to Evaluate the Safety and Efficacy of T92 in Pediatric Patients With Tourette Syndrome

NCT05188274
View directory record Official record
Conditions
Tourette Syndrome in Children, Tourette Syndrome in Adolescence
Interventions
T92, Placebo
Dietary Supplement
Lead sponsor
Tasly Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Sep 23, 2026, 5:02 PM EDT
Completed No phase listed Observational

Evaluation and Follow-up of Individuals With Obsessive-Compulsive Disorder and Related Conditions

NCT00004550
View directory record Official record
Conditions
Anorexia Nervosa, Obsessive Compulsive Disorder, Tourette Syndrome, Trichotillomania
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

NCT01727713
View directory record Official record
Conditions
Tourette's Disorder, Tic Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
7 Years to 18 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
Dothan, Alabama • Goodyear, Arizona • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Sep 23, 2026, 5:02 PM EDT
Terminated Phase 3 Interventional Results available

Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents

NCT03567291
View directory record Official record
Conditions
Tourette Syndrome
Interventions
TEV-50717, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
33
States / cities
Dothan, Alabama • Rogers, Arkansas • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 4 Interventional Results available

Guanfacine in Children With Tic Disorders

NCT01547000
View directory record Official record
Conditions
Tourette Disorder, Tourette Syndrome
Interventions
placebo, extended-release guanfacine (Intuniv)
Drug
Lead sponsor
Yale University
Other
Eligibility
6 Years to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
New Haven, Connecticut • Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Sep 23, 2026, 5:02 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

NCT06021522
View directory record Official record
Conditions
Tourette Syndrome
Interventions
Ecopipam
Drug
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
6 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
44
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Withdrawn Phase 2 Interventional

A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome

NCT02217007
View directory record Official record
Conditions
Tourette Syndrome
Interventions
SNC-102 sustained release tablet
Drug
Lead sponsor
Synchroneuron Inc.
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 23, 2026, 5:02 PM EDT
Recruiting Not applicable Interventional

Strengthening Tourette Treatment OPtions Using TMS to Improve CBIT, a Double-blind, Randomized, Controlled Study

NCT05705999
View directory record Official record
Conditions
Tourette Syndrome
Interventions
transcranial magnetic stimulation
Device
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 23, 2026, 5:02 PM EDT
Completed No phase listed Observational

Magnetic Resonance Spectroscopy to Evaluate Tourette s Syndrome

NCT00030953
View directory record Official record
Conditions
Tourette Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
14 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 23, 2026, 5:02 PM EDT
Terminated Phase 2 Interventional Results available

Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome

NCT03732534
View directory record Official record
Conditions
Tourette Syndrome
Interventions
NBI-98854
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
6 Years to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Anaheim, California • San Diego, California • Gulf Breeze, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Sep 23, 2026, 5:02 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome

NCT03530293
View directory record Official record
Conditions
Tourette Syndrome
Interventions
Valbenazine, Placebo oral capsule
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
6 Years to 17 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
48
States / cities
Sun City, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 43 more
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome

NCT02679079
View directory record Official record
Conditions
Tourette Syndrome
Interventions
NBI-98854, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
6 Years to 17 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
44
States / cities
Sun City, Arizona • Springdale, Arkansas • Long Beach, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acids in Tourette's Disorder

NCT01315327
View directory record Official record
Conditions
Tourette's Disorder
Interventions
Omega-3 Fatty Acids, Olive oil
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
6 Years to 18 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 4 Interventional

Treatment of Obsessive-Compulsive Disorder

NCT00000373
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
olanzapine + fluoxetine, placebo + fluoxetine
Drug
Lead sponsor
University of Florida
Other
Eligibility
14 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2003
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 1 Interventional

Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome

NCT02256475
View directory record Official record
Conditions
Tourette Syndrome
Interventions
NBI-98854
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
6 Years to 18 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
San Diego, California • Kissimmee, Florida • St. Petersburg, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Sep 23, 2026, 5:02 PM EDT
Not listed Not applicable Interventional

Pilot Study for Use of Dysport in Treatment of Vocal Tics in Patients With Tourette's Syndrome

NCT02187679
View directory record Official record
Conditions
Tourette Syndrome, Chronic Vocal Tic
Interventions
Abobotulinum toxin A
Drug
Lead sponsor
Detroit Clinical Research Center
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 9, 2015 · Synced Sep 23, 2026, 5:02 PM EDT
Recruiting No phase listed Observational

A Multicenter Pediatric Deep Brain Stimulation Registry

NCT06585618
View directory record Official record
Conditions
Dystonia, Epilepsy in Children, Cerebral Palsy, Tourette Syndrome, Obsessive-Compulsive Disorder, Neurologic Disorder, Movement Disorders in Children, Movement Disorders, Deep Brain Stimulation
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ecopipam Treatment of Tourette Syndrome

NCT01244633
View directory record Official record
Conditions
Tourette's Syndrome
Interventions
Ecopipam
Drug
Lead sponsor
Psyadon Pharma
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
4
States / cities
Baltimore, Maryland • Summit, New Jersey • Manhasset, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Sep 23, 2026, 5:02 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Investigation of Neurofeedback With Real-Time fMRI in Healthy Volunteers and Patients With Hyperkinetic Movement Disorders

NCT00885040
View directory record Official record
Conditions
Movement Disorder, Tourette Syndrome, Healthy Volunteer
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 60 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2019 · Synced Sep 23, 2026, 5:02 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Exploring the Role of Neuroactive Steroids in Tourette Syndrome

NCT05281445
View directory record Official record
Conditions
Tourette Syndrome in Children
Interventions
Tic suppression task
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
8 Years to 12 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 23, 2026, 5:02 PM EDT
Active, not recruiting Not applicable Interventional

Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals

NCT01075672
View directory record Official record
Conditions
Obsessive Compulsive Disorder, Body Dysmorphic Disorder, Tourette Syndrome, Trichotillomania, Panic Disorder, Social Phobia, Generalized Anxiety Disorder, Depression, Post-Traumatic Stress Disorder, Attention Deficit Hyperactivity Disorder, Eating Disorder, Specific Phobia, General Medical Condition
Interventions
Cognitive behavioral therapy (CBT)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder

NCT01904773
View directory record Official record
Conditions
Tourette Syndrome
Interventions
AZD5213 and placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 17 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
7
States / cities
Orange, California • St. Petersburg, Florida • Summit, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

NCT01416441
View directory record Official record
Conditions
Tourette's Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
7 Years to 18 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
36
States / cities
Dothan, Alabama • Little Rock, Arkansas • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Sep 23, 2026, 5:02 PM EDT
Recruiting Phase 2 Interventional

CBIT+TMS R33 Phase

NCT06678737
View directory record Official record
Conditions
Tics, Tourette Syndrome
Interventions
CBIT +cTBS, CBIT +sham cTBS
Other
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 23, 2026, 5:02 PM EDT